November
Venture Capital & Private Equity
Investment Challenges and Opportunities in Emerging Biotech Markets
Our Past Agenda
Private Equity, Venture Capital & Strategic Partnerships
Drug Discovery Approaches towards Unlocking the Hard to Drug Proteome
Igor O. Nasonkin,
CEO,
Phythera Therapeutics
Private Equity, Venture Capital & Strategic Partnerships
Collaborative Chemistry: The Business of Partnerships in Drug Innovation (Topic TBC)
Klaus Simonsen,
Vice President, Head of External Research & Innovation,
Lundbeck
Private Equity, Venture Capital & Strategic Partnerships
How Strategic Partnerships Revolutionize Pharma R&D
Private Equity, Venture Capital & Strategic Partnerships
Strategic Alliances and Investment Strategies: Fueling the Future of Drug Discovery
Private Equity, Venture Capital & Strategic Partnerships
Strategic Alliances and Investment Strategies: Fueling the Future of Drug Discovery
Private Equity & Venture Capital
Maximizing ROI in Clinical Trials: Navigating Risk, Innovation, and Opportunity
Private Equity & Venture Capita
Balancing Cost-Effectiveness with Data Reliability in Decentralized Models
Private Equity & Venture Capital
Exploring the Key Strategies for Improving the Cost-Efficiency of Clinical Trials and Increasing ROI for Investors?
Private Equity & Venture Capital
Evaluating the Role of Strategic Partnerships in Mitigating Risks and Enhancing Funding or Expertise for Clinical Trials
Engage in Real Conversations That Matter
Our unique roundtable format fosters meaningful dialogue—not lectures—so you gain actionable insights from every discussion. Choose up to four roundtable sessions, each limited to 20 participants, and connect with senior-level peers in a relaxed, collaborative setting.
Further Information
Interested in attending this virtual roundtable or running your own? Drop us a message today and we will get in touch
Here To Help
Need help registering your team? Just get in touch and a member of the team will be happy to help.